Home LiteratureArticle Details
PMID: 19654296 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Validation Study

Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations.

Cancer research ·Vol. 69 ·No. 16 ·2009-08-15 ·Pages 6660-7

Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, Karchin R

Abstract

Large-scale sequencing of cancer genomes has uncovered thousands of DNA alterations, but the functional relevance of the majority of these mutations to tumorigenesis is unknown. We have developed a computational method, called Cancer-specific High-throughput Annotation of Somatic Mutations (CHASM), to identify and prioritize those missense mutations most likely to generate functional changes that enhance tumor cell proliferation. The method has high sensitivity and specificity when discriminating between known driver missense mutations and randomly generated missense mutations (area under receiver operating characteristic curve, >0.91; area under Precision-Recall curve, >0.79). CHASM substantially outperformed previously described missense mutation function prediction methods at discriminating known oncogenic mutations in P53 and the tyrosine kinase epidermal growth factor receptor. We applied the method to 607 missense mutations found in a recent glioblastoma multiforme sequencing study. Based on a model that assumed the glioblastoma multiforme mutations are a mixture of drivers and passengers, we estimate that 8% of these mutations are drivers, causally contributing to tumorigenesis.

MeSH Terms
Algorithms Cell Transformation, Neoplastic/genetics Computational Biology/methods Databases, Genetic Genome-Wide Association Study/methods Glioblastoma/classification,genetics Humans Mutation, Missense/physiology Neoplasms/classification,genetics Polymorphism, Single Nucleotide ROC Curve Sensitivity and Specificity Software Design
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Carter Hannah
Department of Biomedical Engineering and Institute for Computational Medicine, Johns Hopkins University, Baltimore, Maryland 21218, USA.
Chen Sining
Isik Leyla
Tyekucheva Svitlana
Velculescu Victor E
Kinzler Kenneth W
Vogelstein Bert
Karchin Rachel
References (41)
41 references, click to expand
  1. Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma.
    Mol Cancer. 2008 Nov 06;7:84 PMID: 18990233
  2. COSMIC 2005.
    Br J Cancer. 2006 Jan 30;94(2):318-22 PMID: 16421597
  3. An integrated genomic analysis of human glioblastoma multiforme.
    Science. 2008 Sep 26;321(5897):1807-12 PMID: 18772396
  4. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Acta Neuropathol. 2008 Dec;116(6):597-602 PMID: 18985363
  5. Database resources of the National Center for Biotechnology Information.
    Nucleic Acids Res. 2008 Jan;36(Database issue):D13-21 PMID: 18045790
  6. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
    Am J Pathol. 2009 Apr;174(4):1149-53 PMID: 19246647
  7. Human non-synonymous SNPs: server and survey.
    Nucleic Acids Res. 2002 Sep 1;30(17):3894-900 PMID: 12202775
  8. Cytochrome P450 pharmacogenetics and cancer.
    Oncogene. 2006 Mar 13;25(11):1679-91 PMID: 16550168
  9. Somatic alterations in brain tumors.
    Oncol Rep. 2008 Jul;20(1):203-10 PMID: 18575738
  10. Protein kinase C-associated kinase can activate NFkappaB in both a kinase-dependent and a kinase-independent manner.
    J Biol Chem. 2003 Jun 13;278(24):21526-33 PMID: 12676934
  11. p53 polymorphisms: cancer implications.
    Nat Rev Cancer. 2009 Feb;9(2):95-107 PMID: 19165225
  12. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
    Hum Mutat. 2009 Jan;30(1):7-11 PMID: 19117336
  13. Furin-, ADAM 10-, and gamma-secretase-mediated cleavage of a receptor tyrosine phosphatase and regulation of beta-catenin's transcriptional activity.
    Mol Cell Biol. 2006 May;26(10):3917-34 PMID: 16648485
  14. Patterns of somatic mutation in human cancer genomes.
    Nature. 2007 Mar 8;446(7132):153-8 PMID: 17344846
  15. BSD: a novel domain in transcription factors and synapse-associated proteins.
    Trends Biochem Sci. 2002 Apr;27(4):168-70 PMID: 11943536
  16. Role of IRS and PHIP on insulin-induced tyrosine phosphorylation and distribution of IRS proteins.
    Cell Struct Funct. 2007;32(1):69-78 PMID: 17634669
  17. Distinguishing cancer-associated missense mutations from common polymorphisms.
    Cancer Res. 2007 Jan 15;67(2):465-73 PMID: 17234753
  18. Prediction of deleterious human alleles.
    Hum Mol Genet. 2001 Mar 15;10(6):591-7 PMID: 11230178
  19. Prediction of cancer driver mutations in protein kinases.
    Cancer Res. 2008 Mar 15;68(6):1675-82 PMID: 18339846
  20. Androgens induce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP human prostate cancer cells.
    Mol Cell Endocrinol. 2001 Sep;182(2):181-92 PMID: 11514053
  21. PIK3CA alterations in primary (de novo) and secondary glioblastomas.
    Acta Neuropathol. 2007 Mar;113(3):295-302 PMID: 17235514
  22. PTEN signaling pathways in glioblastoma.
    Cancer Biol Ther. 2008 Sep;7(9):1321-5 PMID: 18836294
  23. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes.
    Genome Res. 2005 Aug;15(8):1034-50 PMID: 16024819
  24. Aligning multiple genomic sequences with the threaded blockset aligner.
    Genome Res. 2004 Apr;14(4):708-15 PMID: 15060014
  25. The consensus coding sequences of human breast and colorectal cancers.
    Science. 2006 Oct 13;314(5797):268-74 PMID: 16959974
  26. The Universal Protein Resource (UniProt): an expanding universe of protein information.
    Nucleic Acids Res. 2006 Jan 1;34(Database issue):D187-91 PMID: 16381842
  27. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster.
    Trends Immunol. 2002 Jun;23(6):301-4 PMID: 12072369
  28. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.
    Int J Cancer. 2009 Apr 1;124(7):1669-74 PMID: 19107936
  29. The novel human HUEL (C4orf1) protein shares homology with the DNA-binding domain of the XPA DNA repair protein and displays nuclear translocation in a cell cycle-dependent manner.
    Int J Biochem Cell Biol. 2002 May;34(5):487-504 PMID: 11906820
  30. Predicting deleterious amino acid substitutions.
    Genome Res. 2001 May;11(5):863-74 PMID: 11337480
  31. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2.
    Cell Cycle. 2007 Mar 15;6(6):705-13 PMID: 17374994
  32. Improving functional annotation of non-synonomous SNPs with information theory.
    Pac Symp Biocomput. 2005;:397-408 PMID: 15759645
  33. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
    Science. 2009 Apr 10;324(5924):261-5 PMID: 19359588
  34. ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells.
    J Biol Chem. 2008 Oct 3;283(40):27230-8 PMID: 18660502
  35. IDH1 and IDH2 mutations in gliomas.
    N Engl J Med. 2009 Feb 19;360(8):765-73 PMID: 19228619
  36. PHF2, a novel PHD finger gene located on human chromosome 9q22.
    Mamm Genome. 1999 Mar;10(3):294-8 PMID: 10051327
  37. Polysialylated NCAM represses E-cadherin-mediated cell-cell adhesion in pancreatic tumor cells.
    Gastroenterology. 2008 May;134(5):1555-66 PMID: 18384787
  38. Thrombin generation and the pathogenesis of cancer.
    Semin Thromb Hemost. 2006 Apr;32 Suppl 1:61-8 PMID: 16673267
  39. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
    Science. 2008 Sep 26;321(5897):1801-6 PMID: 18772397
  40. The genomic landscapes of human breast and colorectal cancers.
    Science. 2007 Nov 16;318(5853):1108-13 PMID: 17932254
  41. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression.
    Oncogene. 2006 Oct 30;25(51):6817-30 PMID: 17072330
Article Info
Journal
Cancer research
Abbr.
Cancer Res
ISSN
1538-7445
Published
2009-08-15
Epub
2009-00-04
Pages
6660-7
Language
English
Region
United States
NLM ID
2984705R
PMCID
PMC2763410
Subset
IM
Grants
NCI NIH HHS · CA135877 · United States
PHS HHS · 28XS268 · United States
NCI NIH HHS · CA62924 · United States
NCI NIH HHS · CA43460 · United States
NCI NIH HHS · R37 CA057345 · United States
NCI NIH HHS · R21 CA135877-01 · United States
NCI NIH HHS · R01 CA057345 · United States
NCI NIH HHS · CA57345 · United States
NCI NIH HHS · R37 CA043460 · United States
NCI NIH HHS · CA121113 · United States
NCI NIH HHS · P50 CA062924 · United States
NCI NIH HHS · R21 CA135877 · United States
NCI NIH HHS · R01 CA121113 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com